Abstract
The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Current Vascular Pharmacology
Title:Metabolic Syndrome and Cardiometabolic Risk Factors
Volume: 11 Issue: 6
Author(s): Emilia Papakonstantinou, Vaia Lambadiari, George Dimitriadis and Antonis Zampelas
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease, coronary heart disease, diabetes mellitus, lipids, blood pressure.
Abstract: The metabolic syndrome (MetS) is a cluster of metabolic conditions associated to abdominal obesity, such as elevated blood pressure, impaired glucose tolerance, insulin resistance, elevated triglycerides, and low high-density lipoprotein cholesterol concentrations. Each of the associated conditions has an independent effect, but clustering together they become synergistic, making the risk of developing cardiovascular disease (CVD) greater. There is a big debate as to whether the MetS alone or its associated health conditions are more important for CVD incidence and mortality or whether prevention and/or treatment of the MetS will reduce CVD incidence and mortality. This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
Export Options
About this article
Cite this article as:
Papakonstantinou Emilia, Lambadiari Vaia, Dimitriadis George and Zampelas Antonis, Metabolic Syndrome and Cardiometabolic Risk Factors, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660176
DOI https://dx.doi.org/10.2174/15701611113116660176 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Simultaneous Determination of Six Components in Jingzhiguanxin Tablet by High-Performance Liquid Chromatography
Current Pharmaceutical Analysis Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry PGD and Prenatal Diagnosis: Comparison and Review in Different Genetic Disorders
Current Women`s Health Reviews Mineralocorticoid Receptor Antagonism and Cardiac Remodeling in Ischemic Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2
Cardiovascular & Hematological Disorders-Drug Targets Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging Atrial Fibrillation – New Frontiers in Anticoagulation
Cardiovascular & Hematological Disorders-Drug Targets Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets Medicinal Plants Towards Modeling Skin Cancer
Current Drug Targets The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Induction of Cytoprotective Genes Through Nrf2 / Antioxidant Response Element Pathway: A New Therapeutic Approach for the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Salvaging the Ischemic Heart: Gi-Coupled Receptors in Mast Cells Activate a PKCε/ALDH2 Pathway Providing Anti-RAS Cardioprotection
Current Medicinal Chemistry Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury
Current Pharmaceutical Biotechnology Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Transition of Care for Patients with Diabetes
Current Diabetes Reviews